10-K: Jasper Therapeutics: Briquilimab Progress, Financial Headwinds

Jasper Therapeutics reports positive clinical data for briquilimab in mast cell diseases, but faces significant net losses and substantial doubt about its ability to continue as a going concern.

Summary

• Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting the SCF/KIT pathway, for mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma.
• In the Phase 1b/2a BEACON study for CSU, preliminary data from January 2025 showed rapid onset of clinical efficacy and deep responses, including 100% complete responses in 240mg single-dose cohorts, with a favorable safety profile.
• An atypical absence of UAS7 reduction in 11 of 13 patients in certain CSU cohorts (240mg Q8W and 240mg/180mg Q8W) was reported in July 2025, leading to an investigation that concluded the issue was due to patient selection criteria at certain clinical sites, not product issues.
• Following patient selection improvements, updated data in January 2026 for the 240mg/180mg Q8W CSU cohort showed 83% clinical response by week 3 and 67% complete response at 12 weeks, with UAS7 reductions up to 29 points.
• The Phase 1b/2a SPOTLIGHT study for CIndU, commenced in early 2024, reported positive preliminary data in October 2024 and June 2025, demonstrating deep disease control with 96% of participants achieving a clinical response and 88% achieving a complete response at 120mg or 180mg doses, also with a favorable safety profile.
• An Open Label Extension (OLE) study for CSU and CIndU patients, commenced in 2025, showed deep and durable disease control (75% complete response/well controlled in CSU at week 12; 65% complete/partial response in CIndU at week 16), maintaining a favorable safety profile.
• The Phase 1b ETESIAN study for asthma, commenced in late 2024, reported positive preliminary proof-of-concept data in December 2025, including reduced allergen-induced Late Asthmatic Response (LAR) by 10.4% (6 weeks) and 8.7% (12 weeks) in FEV1 %Max, and lower sputum eosinophil levels.
• The asthma study enrollment was halted in July 2025 due to clinical material being from a drug product lot under investigation for the BEACON study, and further asthma development is contingent on competitive landscape, strategic partnerships, and capital availability.
• The company discontinued its Severe Combined Immunodeficiency (SCID) program and other Investigator Sponsored Trials (ISTs) in stem cell transplant indications in July 2025 to focus exclusively on mast cell disease development programs.
• Jasper Therapeutics reported significant net losses of $75.8 million in 2025 and $71.3 million in 2024, with negative operating cash flows of $77.2 million and $62.6 million for the respective years, leading to an accumulated deficit of $316.7 million as of December 31, 2025.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern beyond one year from the filing date, as its cash and cash equivalents of $28.7 million as of December 31, 2025, are insufficient to fund ongoing operations for at least twelve months.
• A corporate reorganization in July 2025 included a workforce reduction of approximately 50% (22 employees) to extend cash runway, incurring $2.3 million in severance costs.
• In December 2025, the company ceased vivarium operations, terminated 3 research personnel, and recognized an impairment loss of $1.1 million.
• The company raised net proceeds of $27.5 million in September 2025 through an underwritten public offering and an additional $6.5 million in 2025 from an ATM offering.
• Shareholder class action and derivative complaints were filed in September and November 2025, respectively, alleging material misstatements or omissions related to clinical studies, which the company intends to defend vigorously.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging report. While clinical data for briquilimab in mast cell diseases shows promise, the significant net losses, negative cash flow, and explicit 'going concern' warning highlight severe financial instability. The corporate reorganization and program discontinuations, though aimed at extending cash runway, underscore the precarious financial position, further compounded by ongoing shareholder litigation.

Positives

• Briquilimab demonstrated a rapid onset of clinical efficacy in CSU, with clinical responses seen as early as 1 week post-dose and complete responses observed as early as week 2 post-dose.
• Deep and meaningful clinical responses were achieved in CSU, with 100% of patients in the 240mg single dose cohorts achieving complete responses in the first 8 weeks, and 67% of participants in the 240mg/180mg Q8W cohort reporting a complete response at 12 weeks after patient selection adjustments.
• Briquilimab exhibited a favorable safety profile across CSU, CIndU, and OLE studies, with KIT-related adverse events generally transient, low-grade, and few discontinuations.
• In the CIndU SPOTLIGHT study, 96% of participants achieved a clinical response, and 88% of those dosed at 120mg or 180mg achieved a complete response within the preliminary analysis period.
• The Open Label Extension study showed deep and durable disease control for both CSU (75% complete response or well controlled at week 12) and CIndU (65% complete or partial response at week 16).
• Positive proof-of-concept data from the ETESIAN study in asthma indicated reduced allergen-induced Late Asthmatic Response (LAR) by 10.4% at 6 weeks and 8.7% at 12 weeks (FEV1 %Max), and lower sputum eosinophil levels.
• The company successfully raised $27.5 million in net proceeds from an underwritten public offering in September 2025 and $6.5 million from an ATM offering in 2025, providing additional capital.
• Internal control over financial reporting was evaluated as effective as of December 31, 2025.

Negatives

• The company incurred significant net losses of $75.8 million in 2025 and $71.3 million in 2024.
• Negative operating cash flows were reported at $77.2 million in 2025 and $62.6 million in 2024.
• An accumulated deficit of $316.7 million was recorded as of December 31, 2025.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern beyond one year from the filing date, as current cash and cash equivalents ($28.7 million) are insufficient to fund operations for at least twelve months.
• An atypical absence of UAS7 reduction in 11 of 13 patients in certain CSU cohorts (240mg Q8W and 240mg/180mg Q8W) was observed in July 2025, attributed to patient selection issues.
• Enrollment in the Phase 1b asthma study was halted in July 2025 due to concerns about the clinical material's drug product lot, which was under investigation.
• The SCID program and other Investigator Sponsored Trials (ISTs) were discontinued in July 2025, leading to a corporate reorganization and a ~50% workforce reduction (22 employees) with associated costs of $2.3 million.
• Vivarium operations ceased in December 2025, resulting in the termination of 3 research personnel and a $1.1 million impairment loss.
• The company is facing shareholder class action and derivative complaints alleging material misstatements or omissions related to clinical studies, which could lead to significant legal costs and reputational damage.
• Public Warrants have a high exercise price of $115.00 per share for every ten warrants, making them likely to expire worthless given the current stock price of $1.83 as of December 31, 2025.

Risks

• Incurred significant net losses and negative operating cash flows since inception, raising substantial doubt about the ability to continue as a going concern.
• Will need substantial additional funding, which may not be available on acceptable terms or at all, potentially forcing delays, reductions, or elimination of research and product development programs or future commercialization efforts.
• Substantially dependent on the success of briquilimab; failure to complete development, obtain approval, or commercialize in a timely manner would harm the business.
• Delays in the commencement or completion of clinical trials could result in increased costs and delay the ability to establish strategic collaborations.
• May not be successful in efforts to develop and commercialize briquilimab in additional indications or to identify additional product candidates, potentially preventing the company from becoming a commercial stage company or generating revenues.
• Limited resources may be expended to pursue a particular product candidate or indication and fail to capitalize on more profitable or successful opportunities.
• Product candidates may cause serious adverse events, undesirable side effects, or unexpected characteristics, which could delay or prevent regulatory approval, limit commercial potential, or result in significant negative consequences.
• Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, and current limited scope results may not be replicated.
• No history of obtaining regulatory approval for a drug, may never receive regulatory approval for any product candidates, and therefore may never generate revenues from product sales.
• Faces significant competition in an environment of rapid technological change; competitors may achieve regulatory approval before the company or develop safer, more advanced, or more effective therapies.
• If clinical trials of product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, additional costs or delays in completing development and commercialization may be incurred.
• Relies on third parties to conduct preclinical and clinical trials; if these third parties do not successfully carry out contractual duties, meet deadlines, or comply with regulatory requirements, regulatory approval or commercialization may be hindered.
• Relies on a single manufacturer (Lonza) for clinical supply; loss of this manufacturer or failure to comply with FDA regulations could prevent finding an alternative source or scaling up manufacturing.
• Highly dependent on intellectual property licensed from third parties (Amgen, Stanford); termination of any of these licenses could result in the loss of significant rights.
• Commercial success depends on the ability to obtain, maintain, and protect intellectual property and proprietary technology; patents may not provide competitive advantage or may be challenged.
• Faces an inherent risk of product liability exposure related to testing in human clinical trials and commercial sales, potentially leading to substantial liabilities.
• Product candidates are complex and difficult to manufacture, which could lead to delays in development or commercialization, or limit supply.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines, penalties, or significant costs.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Failure to obtain marketing approval in foreign jurisdictions would prevent product candidates from being marketed in such jurisdictions, impairing revenue generation.
• Even if regulatory approval is obtained, approved products may be subject to post-approval studies and ongoing regulatory requirements; failure to comply could lead to withdrawal of approval.
• Interim top-line and preliminary results from clinical trials may change as more patient data become available and are subject to audit and verification procedures.
• Seeking Fast Track or other accelerated review designations may not lead to faster development or regulatory review or approval process, and will not increase the likelihood of marketing approval.
• May not be able to obtain orphan drug exclusivity, or exclusivity may not prevent the FDA or EMA from approving other competing products.
• Disruptions at the FDA, SEC, and other government agencies, including from government shutdowns or funding changes, could hinder their ability to perform normal business functions.
• An unfavorable reimbursement determination in any major market or an unfavorable change in reimbursement regimes (e.g., price controls) could negatively impact the company.
• Relationships with healthcare providers and third-party payors are subject to applicable anti-kickback, fraud and abuse, anti-bribery, and other healthcare laws and regulations, potentially exposing the company to criminal sanctions, civil penalties, and reputational harm.
• Healthcare and other reform legislation may increase the difficulty and cost to obtain marketing approval and commercialize product candidates and affect prices.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and insider trading.
• Laws and regulations governing any international operations may preclude developing, manufacturing, and selling certain product candidates outside the United States and require costly compliance programs.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities or inhibit the ability to collect and process data globally.
• Loss of key management personnel or failure to recruit additional highly skilled personnel could impair development and identification of new product candidates.
• Limited track record of the management team as an operating company; failures in operational execution may materially impact commercial prospects.
• Will need to grow the size of the organization and may experience difficulties in managing this growth.
• Insurance policies may be inadequate and potentially expose the company to unrecoverable risks.
• Internal computer systems, or those of third-party vendors, collaborators, or other contractors, may fail or suffer security breaches, disrupting product development or compromising sensitive information.
• Artificial intelligence presents risks and challenges, including security risks to confidential information and potential compliance costs due to uncertain regulatory environments.
• Unstable market and economic conditions may have serious adverse consequences on the business and financial condition.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations and financial condition.
• The market price of securities may decline and continue to be volatile due to various factors, including adverse regulatory decisions, clinical trial results, and general market conditions.
• Insiders have substantial control (approximately 15.1% of outstanding common stock as of January 31, 2026), which could limit other stockholders' ability to affect the outcome of key transactions.
• Incurred and will continue to incur significant increased expenses and administrative burdens as a public company.
• Failure to comply with the continued listing requirements of the Nasdaq Capital Market could result in delisting and negatively impact the stock price and ability to access capital markets.
• Failure to timely and effectively implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act could negatively impact the business.
• Reliance on certain exemptions from disclosure requirements available to smaller reporting companies could make securities less attractive to investors.
• Future sales, or the perception of future sales, by the company or its stockholders in the public market, or the issuance of rights to purchase common stock, could result in additional dilution and cause the market price to decline.
• No current plans to pay cash dividends on common stock for the foreseeable future.
• Anti-takeover provisions in the Certificate of Incorporation and under Delaware law could make an acquisition more difficult and may prevent attempts by stockholders to replace or remove current management.
• Exclusive forum provisions in the Certificate of Incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Exercise of outstanding warrants to purchase shares of common stock would increase the number of shares eligible for future resale and result in dilution to stockholders.
• Public Warrants may never be 'in the money' and may expire worthless, and their terms may be amended in a manner adverse to a holder if holders of at least 50% of the then-outstanding Public Warrants approve.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for the foreseeable future and does not anticipate generating revenues from product sales for several years, if ever. Its transition to profitability is dependent on the successful development, approval, and commercialization of product candidates and achieving sufficient revenues. Substantial additional funding will be required to maintain continuing operations, with future clinical studies in asthma contingent on competitive landscape, strategic partnerships, and capital availability. The company intends to become a fully integrated discovery, development, and commercial entity in mast cell therapeutics and plans to broaden its pipeline with additional mast cell indications and next-generation products.

Management Comments

• We believe briquilimab is a unique, humanized, monoclonal antibody that targets the underlying biology of mast cell survival to potentially serve as a therapeutic to prevent mast cell driven diseases.
• We believe that depletion of mast cells in the skin of patients with chronic urticaria or other mast cell driven diseases has the potential to lead to improved disease control for those patients without adequate response to current therapies.
• We believe these recommendations [for patient enrollment in the CSU study] have been effective and we are integrating them into our planned Phase 2b/3 CSU study.
• The positive proof of concept data generated in the ETESIAN study supports further development in the broader asthma population, however, advancing any future clinical studies in asthma would be based on an evaluation of the competitive landscape, the potential for strategic partnerships and capital availability.
• Our management expects that the existing cash and cash equivalents will not be sufficient to fund the Company's operating plans for at least twelve months from the issuance date of these consolidated financial statements.
• Our management plans to monitor expenses and raise additional capital through a combination of public and private equity, debt financings, strategic alliances or licensing arrangements.

Industry Context

StockSavvy.ai notes that Jasper Therapeutics operates in a highly competitive and dynamic biotechnology industry characterized by rapid technological change and significant intellectual property emphasis. The company faces competition from major pharmaceutical and biotechnology companies, as well as smaller specialty firms, academic institutions, and government agencies. Key competitors in the KIT-targeted therapeutic program include Celldex Therapeutics, Blueprint Medicines, Novartis, Sanofi Aventis, and Evommune, Inc., highlighting a crowded field for mast cell disease treatments. The strategic decision to discontinue stem cell transplant programs and focus exclusively on mast cell driven diseases reflects a common industry trend of narrowing focus to optimize resource allocation in capital-constrained environments. The ongoing legal challenges and the 'going concern' warning are significant concerns that could impact investor confidence and the company's ability to secure future funding, a critical factor in the capital-intensive biotech sector.

Comparison to Industry Standards

• The efficacy results for briquilimab in CSU (e.g., 100% complete responses in 240mg SD cohorts, 67% complete response in 240mg/180mg Q8W cohort after adjustments) and CIndU (96% clinical response, 88% complete response at higher doses) appear strong for a clinical-stage asset, warranting comparison to approved therapies like omalizumab (Xolair) and dupilumab (Dupixent) for CSU, and antihistamines for CIndU, as well as other pipeline candidates from competitors such as Celldex Therapeutics' KIT antibody and Blueprint Medicines' small molecule KIT inhibitor.
• The favorable safety profile of briquilimab, with generally transient, low-grade KIT-related adverse events and few discontinuations, is a positive indicator when benchmarked against the potential side effects of existing or developing therapies.
• The proof-of-concept data in asthma (reduced LAR, lower eosinophils) suggests potential, but the company's decision to halt further development without strategic partnerships or capital indicates a cautious approach in a highly competitive and well-established market for asthma treatments, where biologics like omalizumab, dupilumab, mepolizumab, reslizumab, and benralizumab are already available.
• The discontinuation of the SCID and other Investigator Sponsored Trial programs, while a strategic focus, means the company is abandoning areas where it had orphan drug designation, which could have provided market exclusivity benefits if successfully commercialized, a common strategy for smaller biotechs.

Management Changes

Corporate Governance

Legal Proceedings

• On September 19, 2025, a shareholder class action complaint (Grant v. Jasper Therapeutics, Inc., et al.) was filed in the United States District Court for the Northern District of California against the company and certain current and former officers, alleging material misstatements or omissions related to briquilimab clinical studies in violation of federal securities laws, seeking unspecified monetary damages and costs.
• On December 3, 2025, a stipulated order was entered in the class action, appointing co-lead plaintiffs and approving their selection of co-lead counsel.
• On December 16, 2025, a stipulated order was entered in the class action, setting a schedule for the filing and responses to an amended complaint, with defendants' responses due on or about April 20, 2026.
• On November 5, 2025, a shareholder derivative complaint (Bardauskas v. Martell, et al.) was filed in the United States District Court for the Northern District of California, naming certain current and former officers and directors as defendants, alleging claims related to the class action.
• On December 22, 2025, another shareholder derivative complaint (Walsh v. Martell, et al.) was filed in the same court.
• On January 21, 2026, a stipulated order was entered consolidating and staying the derivative actions.
• The company believes the claims raised in these lawsuits are without merit and intends to defend these matters vigorously; however, it is unable to determine whether any loss will occur or to estimate the range of such loss, and thus no amount has been accrued in the financial statements.

Related Party Transactions

• Professor Judith Shizuru, a founder and Board member, received $0.3 million for advisory and consulting services in 2024. No such expense was recorded in 2025.
• The company's Licensed Technology from Stanford (2021 Stanford License Agreement) was created in Professor Judith Shizuru's Stanford laboratory.
• A senior executive of the company joined the board of directors of an information technology service provider that the company utilized. The company incurred $0.9 million in 2025 and $1.4 million in 2024 for IT support services from this provider.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity raises, potential loss of investment due to the 'going concern' doubt, stock price volatility, and impact from ongoing legal proceedings. Anti-takeover provisions and insider control may limit their ability to influence corporate actions, and no dividends are anticipated.
• Employees have been impacted by a corporate reorganization in July 2025, including a ~50% workforce reduction (22 employees), and the termination of 3 research personnel in December 2025, potentially affecting morale and increasing workload for remaining staff. Competition for skilled personnel remains intense.
• Future patients and physicians could benefit from new therapeutic options for mast cell driven diseases (CSU, CIndU, asthma) if briquilimab gains regulatory approval. However, delays in development or failure to commercialize would mean unmet medical needs persist.
• Suppliers and creditors face increased risk due to the company's financial instability and 'going concern' warning, potentially leading to non-payment or delayed payments. Reliance on a single-source manufacturer (Lonza) creates concentration risk.
• Regulatory bodies are engaged with the company for clinical trials and approvals, and potential increased scrutiny may arise due to past clinical trial issues or ongoing legal proceedings.

Next Steps

• Integrate expert panel recommendations on patient enrollment processes into the planned Phase 2b/3 CSU study.
• Evaluate the competitive landscape, potential for strategic partnerships, and capital availability before advancing any future clinical studies in asthma.
• Monitor expenses and raise additional capital through equity or debt financings, collaborations, or licensing arrangements to fund future cash needs.
• Vigorously defend against shareholder class action and derivative complaints.
• Continue to advance briquilimab clinical development programs in chronic urticaria.
• Potentially broaden the pipeline with additional mast cell indications and next-generation products.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt about its ability to continue as a going concern' and having insufficient cash for the next 12 months. While clinical data for briquilimab in mast cell diseases shows promise, the financial instability, coupled with ongoing shareholder litigation and a history of significant losses, presents an extremely high-risk investment profile. The need for substantial additional capital, with no assurance of availability on acceptable terms, makes the stock highly speculative. The high exercise price of public warrants compared to the current stock price further indicates a lack of confidence in significant near-term appreciation, suggesting a strong sell recommendation for seasoned investors.

Keywords

Biotechnology, Clinical-stage, Mast cell diseases, Briquilimab, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Asthma, Drug development, Clinical trials, SEC filing, 10-K, Financial reporting, Going concern, Nasdaq, Monoclonal antibody, SCF/KIT pathway, Orphan drug, Warrants, Corporate governance, Shareholder litigation, Workforce reduction, Capital raise